interferon kappa / Shanghai Public Health Clinical Center 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
2 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
interferon kappa / Shanghai Public Health Clinical Center
ChiCTR2000030262_1: Clinical study for combination of anti-viral drugs and type I interferon and inflammation inhibitor TFF2 in the treatment of novel coronavirus pneumonia (COVID-19)

Recruiting
1
30
China
trefoil peptide TFF2 - Shanghai Public Health Clinical Center
Shanghai Public Health Clinical Center 
Novel coronavirus pneumonia (COVID-19)
 
 
ChiCTR2000030262: Clinical study of novel coronavirus (SARS-Cov-2) infection treated with aerosol inhalation (IFN-κ plus anti-inflammatory factor TFF2)

Recruiting
N/A
140
China
Standard therapy plus aerosol inhalation for 3 times (once for every day) ;Standard therapy plus aerosol inhalation for 3 times (once for every 2 days) ;Standard therapy ;Standard therapy plus aerosol inhalation for 6 times (once for every day)
Shanghai Public Health Clinical Center; Shanghai Public Health Clinical Center, Shanghai Municipal Health Commission
Novel Coronavirus Pneumonia (COVID-19)
 
 

Download Options